NCT00167999View on ClinicalTrials.gov

Study Evaluating Piperacillin-Tazobactam on Certain Bacteria in Hematology and Oncology Units

CompletedOBSERVATIONAL
Enrollment

200

Participants

Timeline

Start Date

February 28, 2005

Conditions
Gram-Positive Bacterial InfectionsEscherichia Coli InfectionsKlebsiella Infections
Interventions
DRUG

piperacillin-tazobactam

Trial Locations (1)

133-792

Seoul

All Listed Sponsors
lead

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

NCT00167999 - Study Evaluating Piperacillin-Tazobactam on Certain Bacteria in Hematology and Oncology Units | Biotech Hunter | Biotech Hunter